Osiris’ products include Grafix® and Ovation® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair and the latest addition to Osiris’ line of products, OvationOS™, a ...
A partnership between Osiris Therapeutics and Net Health has broadened the availability of Grafix, a human placental tissue product used to treat chronic wounds. At present, Grafix is marketed by ...
LONDON, March 31, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a peer-reviewed study in the Advances in Wound Care ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound ...
Osiris Therapeutics, Inc. OSIR, reported today that its multi-center, randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to standard of care in patients with ...
(Reuters) - Shares of Osiris Therapeutics Inc rose 15 percent on Wednesday, after U.S. health regulators said the stem-cell technology company's wound treatment was eligible for reimbursement when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results